Pharmaceuticals, Biotechnology and Life Sciences
New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs…
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to…
Wide-ranging A*STAR and SERI partnership will accelerate the development of novel developmental candidates in the areas of ophthalmology and oncology,…
MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement…
SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical…
PDUFA target action date set for December 20, 2024THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.…
– Patient characteristics are consistent with other DLB studies – PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics,…
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820…
Company to Host Conference Call Today, October 31, at 4:30pm ETBOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) — INmune…
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company…